Hepatic Artery Administration
Hepatic Artery Administration - Related Videos
04:46
Targeting Liver Tumors with Oncolytic Viruses via the Hepatic Artery
0 Views •
2025
The video demonstrates locoregional delivery of oncolytic viruses through hepatic arterial injection as a therapeutic approach for hepatocellular carcinoma. These viruses selectively replicate in tumor cells, inducing cell lysis and releasing tumor cell-associated antigens. This process triggers immunogenic cell death, inducing an anti-tumor response.
18:47
Surgical Procedures for a Rat Model of Partial Orthotopic Liver Transplantation with Hepatic Arterial Reconstruction
0 Views •
Cited by 22 •
2013
Orthotopic liver transplantation in rats is an indispensable experimental model for biomedical research. Here we present our surgical procedures for orthotopic rat liver transplantation with hepatic arterial reconstruction using a 50% partial graft.
16:19
Heterotopic Auxiliary Rat Liver Transplantation With Flow-regulated Portal Vein Arterialization in Acute Hepatic Failure
0 Views •
Cited by 5 •
2014
Auxiliary liver transplantation provides a temporary support in acute hepatic failure, until regeneration of the failing liver. The heterotopic auxiliary liver transplantation (HALT) with portal vein arterialization (PVA) renders sufficient liver function. We developed an analogous technique in the rat, to examine the influence of the portal vein arterialization on the morphology and function of the graft.
15:05
Compound Administration I
0 Views •
2015
Source: Kay Stewart, RVT, RLATG, CMAR; Valerie A. Schroeder, RVT, RLATG. University of Notre Dame, IN As many research protocols require that a substance be injected into an animal, the route of delivery and the amount of the substance must be accurately determined. There are several routes of administration available in the mouse and rat. Which route to use is determined by several factors of the substance to be injected: the pH of the solution, the volume required for the desired dosage, and...
08:55
Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
0 Views •
Cited by 3 •
2016
Oncolytic virotherapies are under development as novel therapeutics for the treatment of hepatocellular carcinoma (HCC). Here we describe a method for locoregional therapy of HCC via hepatic arterial administration of oncolytic virus.
FAQs
Vascular anatomy and blood flow determine where an administered agent travels within the liver and how evenly it reaches the intended tissue. Variations in arterial pathways can therefore influence distribution, concentration, and treatment effect. Before administration, clinicians must account for these factors because the same catheter position or delivered agent may not produce identical exposure in every patient.
Catheter placement controls whether the therapy enters the intended hepatic circulation. Guided advancement through the vascular system helps clinicians position the catheter in relation to the liver’s arterial supply, while inaccurate placement may alter regional delivery. Proper positioning is consequently linked to predictable exposure and supports the goal of concentrating treatment in liver tissue rather than distributing it broadly.
Regional delivery can create a higher concentration in targeted liver tissue while potentially reducing the amount reaching the rest of the body. This advantage is not automatic: it depends on vascular anatomy, hepatic blood flow, and catheter position. Clinicians therefore evaluate these conditions when considering whether direct arterial administration is likely to provide useful targeting for a selected liver condition.
Clinicians introduce a catheter through the vascular system, guide it into the hepatic circulation, and administer the selected drug, contrast agent, or other therapy through the catheter. The process requires attention to arterial anatomy and catheter location before delivery. Monitoring during and after administration helps assess the intended regional treatment and identify possible complications.
Clinicians may consider this approach when a liver condition is localized and a regional treatment strategy is appropriate. The overview specifically identifies selected liver conditions, including uses involving localized anticancer agents and embolic materials. Its relevance is that therapy can be directed toward liver tissue at a targeted concentration, rather than relying solely on broader systemic distribution.
Monitoring focuses on the conditions that influence delivery and safety, particularly vascular anatomy, hepatic blood flow, and catheter placement. Clinicians also watch for complications associated with the procedure and the administered therapy. Attention to these factors helps determine whether the agent reached the intended regional circulation and whether additional clinical management is needed after administration.